Angela Walsh - Virios Therapeutics SVP CFO
| VIRI Stock | USD 0.18 0.02 10.00% |
Insider
Angela Walsh is SVP CFO of Virios Therapeutics Llc
| Age | 57 |
| Address | 44 Milton Avenue, Alpharetta, GA, United States, 30009 |
| Phone | 866 620 8655 |
| Web | https://www.virios.com |
Virios Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5432) % which means that it has lost $0.5432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9514) %, meaning that it created substantial loss on money invested by shareholders. Virios Therapeutics' management efficiency ratios could be used to measure how well Virios Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.33. The Virios Therapeutics' current Return On Capital Employed is estimated to increase to -1.36. The Virios Therapeutics' current Net Tangible Assets is estimated to increase to about 10.7 M, while Total Assets are projected to decrease to under 4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Justin Klee | Amylyx Pharmaceuticals | 33 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Jonathan JD | Compass Therapeutics | N/A | |
| Prof MD | Ventyx Biosciences | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| MBA JD | Ventyx Biosciences | 56 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Vered MBA | Compass Therapeutics | 53 | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
Management Performance
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.54 |
Virios Therapeutics Llc Leadership Team
Elected by the shareholders, the Virios Therapeutics' board of directors comprises two types of representatives: Virios Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virios. The board's role is to monitor Virios Therapeutics' management team and ensure that shareholders' interests are well served. Virios Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virios Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Duncan, Chairman CEO | ||
| Carol Duffy, Chief Advisor | ||
| William MD, Founder Director | ||
| Ralph MPH, Senior Operations | ||
| Angela Walsh, SVP CFO |
Virios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virios Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 3.86 M | ||||
| Shares Outstanding | 19.26 M | ||||
| Shares Owned By Insiders | 9.71 % | ||||
| Shares Owned By Institutions | 8.14 % | ||||
| Number Of Shares Shorted | 100.48 K | ||||
| Price To Book | 2.59 X | ||||
| EBITDA | (5.45 M) | ||||
| Net Income | (5.3 M) |
Currently Active Assets on Macroaxis
| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce | |
| MSFT | Microsoft | |
| GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virios Therapeutics Llc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Virios Stock analysis
When running Virios Therapeutics' price analysis, check to measure Virios Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virios Therapeutics is operating at the current time. Most of Virios Therapeutics' value examination focuses on studying past and present price action to predict the probability of Virios Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virios Therapeutics' price. Additionally, you may evaluate how the addition of Virios Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Virios Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Virios Therapeutics. If investors know Virios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Virios Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.28) | Return On Assets (0.54) | Return On Equity (0.95) |
The market value of Virios Therapeutics Llc is measured differently than its book value, which is the value of Virios that is recorded on the company's balance sheet. Investors also form their own opinion of Virios Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Virios Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Virios Therapeutics' market value can be influenced by many factors that don't directly affect Virios Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Virios Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Virios Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Virios Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.